Novel 1-(2-pyrimidin-2-yl)piperazine derivatives as selective monoamine oxidase (MAO)-A inhibitors
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, vol.32, no.1, pp.193-202, 2017 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 32 Issue: 1
- Publication Date: 2017
- Doi Number: 10.1080/14756366.2016.1247054
- Journal Name: JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Index Chemicus (IC)
- Page Numbers: pp.193-202
- Keywords: Depression, Lipinski's rule of five, Molinspiration, MolSoft, monoamine oxidase A, (2-pyrimidinyl)piperazine, ANTIPSYCHOTIC AGENTS, ANTI-DEPRESSANT, MAO-A, ANTIDEPRESSANT, BUSPIRONE, PHARMACOLOGY, ANXIOLYTICS, SUBSTRATE, DOCKING, ANALOGS
- Bilecik Şeyh Edebali University Affiliated: No
Abstract
In the present study, a new series of 2-[4-(pyrimidin-2-yl) piperazin-1-yl]-2-oxoethyl 4-substituted piperazine- 1-carbodithioate derivatives (2a-n) were synthesized and screened for their monoamine oxidase A and B inhibitory activity. The structures of compounds were elucidated using spectroscopic methods and some physicochemical properties of new compounds were predicted using Molinspiration and MolSoft programs. Compounds 2-[4-(pyrimidin-2-yl) piperazin-1-yl]-2-oxoethyl 4-(4-nitrophenyl) piperazine-1-carbodithioate (2j) and 2-[4-(pyrimidin-2-yl) piperazin-1-yl]-2-oxoethyl 4-benzhydrylpiperazine-1-carbodithioate (2m) exhibited selective MAO-A inhibitory activity with IC50 = 23.10, 24.14 mu M, respectively. Some of the biological results were found in accordance with the obtained in silico data based on Lipinski's fule of five.